UB Paderborn / Katalog / Suche / in CDI

Proton pump inhibitor therapy and potential long-term harm

Current opinion in endocrinology, diabetes, and obesity, 2014-02, Vol.21 (1), p.3-8

2014

Volltextzugriff (PDF)

Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study

The American journal of gastroenterology, 2024-08, Vol.119 (8), p.1525-1535

2024

Volltextzugriff (PDF)

SAPHO Syndrome in Crohn’s Disease Successfully Treated with Ustekinumab: Case Report and Review of the Literature

EMJ. Gastroenterology, 2023-11

2023

Volltextzugriff (PDF)

Should the Mediterranean diet be recommended for inflammatory bowel diseases patients? A narrative review

Frontiers in nutrition (Lausanne), 2023-01, Vol.9, p.1088693-1088693

2023

Volltextzugriff (PDF)

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Journal of clinical medicine, 2024-04, Vol.13 (7), p.1857

2024

Volltextzugriff (PDF)

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Gastroenterology research and practice, 2018-01, Vol.2018, p.4195968-7

2018

Volltextzugriff (PDF)

Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question

Current clinical pharmacology, 2014-02, Vol.9 (1), p.84

2014

Volltextzugriff (PDF)

Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection

Digestive and liver disease, 2022-11, Vol.54 (11), p.1598-1599

2022

Volltextzugriff (PDF)

Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study

Alimentary pharmacology & therapeutics, 2024-06, Vol.59 (12), p.1579-1588

2024

Volltextzugriff (PDF)

Acute fulminant hepatitis E virus genotype 3e infection: description of the first case in Europe

Infectious diseases (London, England), 2015-02, Vol.47 (2), p.113-113

2015

Volltextzugriff (PDF)

Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

Digestive and liver disease, 2023-06, Vol.55 (6), p.695-703

2023

Volltextzugriff (PDF)

“Mucosal healing” in ulcerative colitis:Between clinical evidence and market suggestion

World journal of gastrointestinal pathophysiology, 2014-05, Vol.5 (2), p.54-62

2014

Volltextzugriff (PDF)

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology

Digestive and liver disease, 2022-04, Vol.54 (4), p.428-439

2022

Volltextzugriff (PDF)

The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable”

Digestive and liver disease, 2020-11, Vol.52 (11), p.1238-1240

2020

Volltextzugriff (PDF)

Screening for active COVID-19 infection prior to biologic therapy in IBD patients: Let's not increase our uncertainty without reducing our concerns

Digestive and liver disease, 2020-11, Vol.52 (11), p.1246-1247

2020

Volltextzugriff (PDF)

No impact of restructuring IBD-related activity during COVID-19 outbreak on patient outcomes. A single Center experience

Digestive and liver disease, 2021-09, Vol.53 (9), p.1076-1078

2021

Volltextzugriff (PDF)

Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence

Expert review of gastroenterology & hepatology, 2017-04, Vol.11 (4), p.339-347

2017

Volltextzugriff (PDF)

Acute kidney injury: an unexpected Isoniazid-related adverse event in a patient with Crohn's disease receiving prophylactic treatment for latent tuberculosis

Digestive and liver disease, 2020-09, Vol.52 (9), p.1065-1066

2020

Volltextzugriff (PDF)

Stricturing Crohn’s disease: what is the role of endoscopic stenting? A systematic review

Clinical endoscopy, 2023-11, Vol.56 (6), p.726-734

2023

Volltextzugriff (PDF)

Stricturing Crohn"s disease: what is the role of endoscopic stenting? A systematic review

Clinical endoscopy, 2023-11, p.726-734

2023

Volltextzugriff (PDF)

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study

Alimentary pharmacology & therapeutics, 2022-07, Vol.56 (1), p.95-109

2022

Volltextzugriff (PDF)

Methotrexate in Crohn's disease: a new face for an old drug?

Expert review of gastroenterology & hepatology, 2016-10, Vol.10 (10), p.1135-1144

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Proton pump inhibitor therapy and potential long-term harm

Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study

SAPHO Syndrome in Crohn’s Disease Successfully Treated with Ustekinumab: Case Report and Review of the Literature

Should the Mediterranean diet be recommended for inflammatory bowel diseases patients? A narrative review

Enteropathic spondyloarthritis: Results from a large nationwide database analysis

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Incident Colorectal Cancer in Inflammatory Bowel Disease

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question

Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection

Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study

Acute fulminant hepatitis E virus genotype 3e infection: description of the first case in Europe

Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

“Mucosal healing” in ulcerative colitis:Between clinical evidence and market suggestion

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology

The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable”

Screening for active COVID-19 infection prior to biologic therapy in IBD patients: Let's not increase our uncertainty without reducing our concerns

No impact of restructuring IBD-related activity during COVID-19 outbreak on patient outcomes. A single Center experience

Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence

Acute kidney injury: an unexpected Isoniazid-related adverse event in a patient with Crohn's disease receiving prophylactic treatment for latent tuberculosis

Stricturing Crohn’s disease: what is the role of endoscopic stenting? A systematic review

Stricturing Crohn"s disease: what is the role of endoscopic stenting? A systematic review

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case–Control IG-IBD Study

Methotrexate in Crohn's disease: a new face for an old drug?

Suchergebnisse filtern